After counsel withdrew for some of the plaintiffs in a huge consolidated legal battle between Gilead Sciences and patients ...

A disruption in federal funds has jeopardized HIV testing and outreach in Mississippi, and researchers warn of a resurgence ...

Pharmaceutical firm Gilead has admitted paying hundreds of thousands of dollars in illegal kickbacks to US doctors between ...

Gilead Sciences has agreed to pay USD 202 million to settle a whistleblower lawsuit that accused the company of engaging in ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Gilead is committed to using its virology expertise to advance HIV treatment and prevention to help end the epidemic. Since 2010, the company has partnered with Emory University in Atlanta to launch A ...

President Donald Trump, in his first term, promised to end America’s HIV epidemic — and he put the resources of the federal ...

GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the ...

Gilead to Pay $202 Million to Settle DOJ Claims Over Speaker Program Kickbacks - Gilead Sciences, Inc. has agreed to pay $202 ...

Gilead Sciences has agreed to pay $202 million to resolve allegations that it violated the Anti-Kickback Statute by using speaker programs to incentivize physicians to prescribe HIV medications.

On April 29, 2025, the U.S. Attorney’s Office for the Southern District of New York (SDNY) announced a $202 million civil False Claims Act ...